Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Immunotherapy offers a promising cancer treatment by activating the host immune system, potentially reducing side effects.
• Traditional immunotherapy often faces limitations due to tumor escape and resistance, leading to modest clinical effects.
• Pharmaceutical nanotechnology presents a viable strategy to address the challenges of conventional immunotherapy.

Purpose of the Study:

• To review recent advancements in immunotherapy and nanomedicine.
• To illustrate the application of nanocarriers in cellular transfer of immune effectors for nanoimmunotherapy.
• To explore how nanocarrier engineering can optimize antitumor responses.

Main Methods:

• Review of current literature on immunotherapy and nanomedicine.
• Illustration of nanocarrier types (micelles, liposomes, polymer-drug conjugates, solid lipid nanoparticles, biodegradable nanoparticles).
• Discussion of nanocarrier design principles tailored to the tumor microenvironment and cellular conditions.

Main Results:

• Nanocarriers can facilitate the delivery of immune effectors for both active and passive nanoimmunotherapy.
• Engineering nanocarriers based on tumor-specific features can enhance their efficacy.
• Optimized nanocarrier strategies can rebalance the host-tumor-nanoparticle interactions to favor antitumor immunity.

Conclusions:

• Nanomedicine offers a powerful approach to overcome limitations in traditional cancer immunotherapy.
• Tailored nanocarrier design is crucial for effective nanoimmunotherapy.
• Nanoimmunotherapy holds significant promise for improving cancer treatment outcomes.